Sign In
Buy SNY
$43.75
-0.230 (-0.523%)
At Close: Jul 21, 2026
Regeneron, SNY's Dupixent Get CHMP Recommendation for Label Expansion
02:45pm, Monday, 23'rd Sep 2024
REGN and SNY get positive CHMP opinion on the label expansion of Dupixent in the EU for eosinophilic esophagitis in children down to 1 year of age.
Sanofi Injects $27M In Neurology Drug Developer Ventyx Biosciences
11:13am, Monday, 23'rd Sep 2024
On Monday, Sanofi SA SNY agreed to make a $27 million strategic investment in Ventyx Biosciences Inc VTYX.
Sanofi's Sarclisa Gets FDA Nod for Expanded Use in Multiple Myeloma
11:01am, Monday, 23'rd Sep 2024
This latest FDA decision marks the first approval for SNY's Sarclisa as a first-line treatment for multiple myeloma patients.
Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant
Sanofi wins US approval for drug combination to treat multiple myeloma
03:40pm, Friday, 20'th Sep 2024
Sanofi won approval for the use of a drug combination with its Sarclisa infusion to treat certain types of newly diagnosed multiple myeloma, where it has previously been used only after standard treat
Sanofi (SNY) ECTRIMS 2024 Investor Science Call Transcript
02:12pm, Friday, 20'th Sep 2024
Sanofi (NASDAQ:SNY ) ECTRIMS 2024 Investor Science Call September 20, 2024 10:00 AM ET Company Participants Thomas Kudsk - IR Jiwon Oh - MD, PhD, St. Michael's Hospital, University of Toronto, Toronto
Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old Recommendation based on a phase 3 study showing a significantly greater proportion
Sanofi says tolebrutinib drug delayed progressive MS by 31%
05:54am, Friday, 20'th Sep 2024
Sanofi said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the disease by 31%, as the French drugmaker eyes a request for approval later thi
Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study
Sanofi Stock Up Almost 23% in 3 Months: Buy, Sell or Hold?
04:01pm, Thursday, 19'th Sep 2024
SNY's reasonable valuation, rising estimates, improving top line and positive pipeline progress are good enough reasons to stay invested in the stock.
NEW YORK, Sept. 17, 2024 /PRNewswire/ -- Report on how AI is driving market transformation- The global squalene market size is estimated to grow by USD 62.9 mn from 2024-2028, according to Technavio.
Regeneron, SNY Win FDA Approval for a Broader Dupixent Label
02:21pm, Monday, 16'th Sep 2024
REGN gets FDA nod for Dupixent for a broader population for the indication of chronic rhinosinusitis with nasal polyps.
US FDA approves manufacturing line for Sanofi's preventive RSV therapy
08:16am, Monday, 16'th Sep 2024
Sanofi said on Monday the U.S. Food and Drug Administration has approved a manufacturing line for its and partner AstraZeneca's preventive respiratory syncytial virus (RSV) therapy.
Sanofi shipping BEYFORTUS® in US to help protect babies against RSV disease; new manufacturing line approved by FDA
08:00am, Monday, 16'th Sep 2024
Company planning for every eligible baby in the US to have access to BEYFORTUS New BEYFORTUS filling line approved by the U.S. Food and Drug Administration (FDA) to expand manufacturing capacity and h
Press Release: Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers
01:00am, Thursday, 12'th Sep 2024
Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers Paris, France, and Houston, Texas, September 12, 2024. As part of its effort to
